Smallpox Vaccine Research at
the Medical College of Wisconsin
Researchers at the Medical College of
Wisconsin have been studying vaccinia virus,
which makes up the smallpox vaccine, for
years as a way of understanding how viruses
and vaccines work at the cellular level.
That research, funded largely by the federal
government, may lead to advances in
preventing and treating smallpox, which
could have ramifications in times of
bioterrorism.
Vaccinia as Smallpox Vaccine
Vaccinia virus was one of the first vaccines
ever developed. Smallpox had killed hundreds
of millions of people through the centuries,
but in the late 1700s medical practitioners
noticed that milkmaids who had been exposed
to cowpox were immune to smallpox. They
began taking cowpox from cows and scratching
it into the arms of people to protect them
against smallpox. At some point, cowpox
virus was replaced by vaccinia virus, which
is 90% identical to smallpox but only rarely
causes health problems.
Modern public health systems worldwide
joined in a campaign to vaccinate
populations against smallpox, and the dread
disease was eradicated globally by the
1970s, at which point vaccination against
the disease was discontinued. However, it is
theoretically possible that a smallpox-like
virus could re-emerge in nature as a result
of the many poxviruses that exist in animal
species. Furthermore, laboratories in the US
and former Soviet Union are known to have
stocks of the virus, perhaps refined as
weapons. Other nations, potentially some
that support terrorism, may also have stores
of weaponized smallpox or the ability to
produce it. Though unlikely, a smallpox
attack would be highly contagious and could
overwhelm communities if it occurs.
“As a first cousin of smallpox, vaccinia
virus offers an ideal opportunity to study a
complex and medically relevant virus,” says
Paula Traktman, PhD, Walter Schroeder
Professor and Chairman of the
Department of Microbiology and Molecular
Genetics at the Medical College of
Wisconsin. She has headed a virus research
laboratory since 1984 and moved to the
Medical College in 1997. “Over the last
15-20 years there has been a revolution in
the study of molecular genetics, which helps
us understand how viruses work.” Vaccinia
virus provides a model to understand
universal biological processes that can
affect everything from birth defects to
cancer. As part of federal anti-bioterrorism
initiatives, Dr. Traktman has also helped
establish an international database to share
all information pertinent to poxviruses and
their vaccines.
Studying vaccinia virus helps researchers
understand the “choreography of the viral
lifecycle,” Dr. Traktman says. Researchers
are examining how the virus enters cells and
duplicates itself, synthesizing thousands of
new viruses within the body that spread to
other cells.
The researchers at the Medical College
seek an alternative to the current smallpox
vaccine by testing compounds for their
ability to act at the intracellular level
and serve as anti-viral drugs if an
infection occurs. An anti-viral drug might
act as protease inhibitors do in
HIV-positive individuals, preventing the
virus from multiplying. There is currently
no antiviral drug to fight smallpox,
although there is some laboratory evidence
that cidovifir may have anti-viral
properties after smallpox exposure. At this
time, it has not been thoroughly tested and
is not available for widespread use.
How Smallpox Spreads
It is estimated that during a smallpox
outbreak in an urban setting, each infected
person could infect 10 more people.
Historically, smallpox kills about 30% of
the people infected with it. If the vaccine
is given within the first four days after
exposure, it will prevent smallpox or
significantly reduce the symptoms and risk
of death. However, initial exposure is
difficult to detect. Early on, there are
only flu-like symptoms; there is no rash and
it is not contagious. After about two weeks,
pox (inflamed lesions) appear in the mouth
and throat. Smallpox is highly contagious at
that point and frequently spreads by
coughing or even speaking. An extreme rash –
hundreds of lesions – spreads to the face,
arms and legs, leaving permanent scars.
Because smallpox virus can be spread
through droplets and aerosols as a very fine
mist, it could spread through ventilation
systems within a building. Should an
outbreak occur, infected individuals will be
quarantined. The room – or building, if
necessary – will be quarantined and
pressurized so that air can flow in but not
out. Bedding, clothing and even furniture
may have to be destroyed because contagious
dry pox may otherwise survive.
In case of a smallpox outbreak,
vaccinations will likely be performed in a
“ring” around the infected person. In other
words, people who have had contact with the
individual or contact with people who know
the individual will receive vaccinations.
Vaccinations of an entire region or the
entire country are not expected to be
necessary.
Because most physicians have never seen
smallpox, the US Centers for Disease Control
and Prevention has been providing
educational materials and seminars to
healthcare providers to help them recognize
and treat smallpox outbreaks.
Will Childhood Vaccination Protect
Against Smallpox?
There is some debate in the scientific
community about whether people vaccinated
against smallpox in childhood still have
immunity from the disease. Dr. Traktman
points to studies that show that while
vaccination loses some of its efficacy over
the years, immunity at the cellular level
may last for decades. In other words, an
individual vaccinated years earlier might
become ill from smallpox, but is much less
likely to die from it. They also may be less
likely to transmit the disease. One study
showed that even people over the age of 50
who were vaccinated as children retained
significant immunity to smallpox. The
biggest problem is that individuals born in
the US since 1972 – tens of millions of
people – have never been vaccinated for
smallpox.
Smallpox vaccine is not currently
available to civilians in the US, although
the CDC has a small amount available for lab
workers who use vaccinia virus and other
poxviruses in their research. The US
government currently has about 15 million of
doses of smallpox vaccine available and has
asked manufacturers to begin producing the
vaccine in mass quantities in the event that
smallpox is used as a bioterror weapon. By
2002 there should be enough vaccine for
everyone in the country.
Article Created: 2001-12-27
Article Updated: 2001-12-28
|